Evaluation of assay kit for detecting SARS-CoV-2 infectio
Not Applicable
- Conditions
- Coronavirus disease 2019
- Registration Number
- JPRN-UMIN000044225
- Lead Sponsor
- Sekisui Medical Co., Ltd.
- Brief Summary
See https://www.ijidonline.com/article/S1201-9712(22)00517-3/fulltext
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who are difficult to obtain clinical samples from. 2) For any reason other than above, patients who were determined by doctor as being unfit to participate in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets does the SARS-CoV-2 rapid diagnostic test kit evaluate for viral detection?
How does the Sekisui Medical rapid test compare to RT-PCR in sensitivity and specificity for SARS-CoV-2 detection?
Are there specific biomarkers used to validate the rapid test's accuracy in detecting active SARS-CoV-2 infection?
What are the potential false-negative rates of the assay kit in asymptomatic or pre-symptomatic COVID-19 cases?
How does the performance of this rapid diagnostic test align with other antigen-based assays in clinical settings?